Virus-host interactomics: New insights and opportunities for antiviral drug discovery

77Citations
Citations of this article
170Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The current therapeutic arsenal against viral infections remains limited, with often poor efficacy and incomplete coverage, and appears inadequate to face the emergence of drug resistance. Our understanding of viral biology and pathophysiology and our ability to develop a more effective antiviral arsenal would greatly benefit from a more comprehensive picture of the events that lead to viral replication and associated symptoms. Towards this goal, the construction of virus-host interactomes is instrumental, mainly relying on the assumption that a viral infection at the cellular level can be viewed as a number of perturbations introduced into the host protein network when viral proteins make new connections and disrupt existing ones. Here, we review advances in interactomic approaches for viral infections, focusing on high-throughput screening (HTS) technologies and on the generation of high-quality datasets. We show how these are already beginning to offer intriguing perspectives in terms of virus-host cell biology and the control of cellular functions, and we conclude by offering a summary of the current situation regarding the potential development of host-oriented antiviral therapeutics.

Cite

CITATION STYLE

APA

de Chassey, B., Meyniel-Schicklin, L., Vonderscher, J., André, P., & Lotteau, V. (2014, November 29). Virus-host interactomics: New insights and opportunities for antiviral drug discovery. Genome Medicine. BioMed Central Ltd. https://doi.org/10.1186/s13073-014-0115-1

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free